Last reviewed · How we verify
Pre-radiotherapy commencement of anastrozole
Pre-radiotherapy commencement of anastrozole is a aromatase inhibitor Small molecule drug developed by Trans Tasman Radiation Oncology Group. It is currently in Phase 3 development for Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Also known as: Arimidex.
Anastrozole inhibits aromatase, reducing estrogen levels in postmenopausal women.
Anastrozole inhibits aromatase, reducing estrogen levels in postmenopausal women. Used for Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
At a glance
| Generic name | Pre-radiotherapy commencement of anastrozole |
|---|---|
| Also known as | Arimidex |
| Sponsor | Trans Tasman Radiation Oncology Group |
| Drug class | aromatase inhibitor |
| Target | aromatase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Anastrozole is a selective aromatase inhibitor that blocks the conversion of androgens to estrogens, thereby lowering circulating estrogen levels which can slow the growth of hormone-sensitive breast cancer cells.
Approved indications
- Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
- Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy
Common side effects
- Hot flashes
- Joint pain
- Fatigue
Key clinical trials
- STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing) (PHASE3)
- Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) (PHASE4)
- Study of Arimidex and Radiotherapy Sequencing (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pre-radiotherapy commencement of anastrozole CI brief — competitive landscape report
- Pre-radiotherapy commencement of anastrozole updates RSS · CI watch RSS
- Trans Tasman Radiation Oncology Group portfolio CI
Frequently asked questions about Pre-radiotherapy commencement of anastrozole
What is Pre-radiotherapy commencement of anastrozole?
How does Pre-radiotherapy commencement of anastrozole work?
What is Pre-radiotherapy commencement of anastrozole used for?
Who makes Pre-radiotherapy commencement of anastrozole?
Is Pre-radiotherapy commencement of anastrozole also known as anything else?
What drug class is Pre-radiotherapy commencement of anastrozole in?
What development phase is Pre-radiotherapy commencement of anastrozole in?
What are the side effects of Pre-radiotherapy commencement of anastrozole?
What does Pre-radiotherapy commencement of anastrozole target?
Related
- Drug class: All aromatase inhibitor drugs
- Target: All drugs targeting aromatase
- Manufacturer: Trans Tasman Radiation Oncology Group — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
- Indication: Drugs for Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy
- Also known as: Arimidex
- Compare: Pre-radiotherapy commencement of anastrozole vs similar drugs
- Pricing: Pre-radiotherapy commencement of anastrozole cost, discount & access